The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index; none of the 46 sources its claims cite is checked for support yet.
A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator
Open accessAbstract
This study compared the efficacy and safety of a human acellular dermal matrix (ADM), D‐ADM, with a conventional care arm and an active comparator human ADM arm, GJ‐ADM, for the treatment of chronic diabetic foot ulcers. The study design was a prospective, randomized controlled trial that enrolled 168 diabetic foot ulcer subjects in 13 centers across 9 states. Subjects in the ADM arms received one application but could receive one additional application of ADM if deemed necessary. Screen failures and early withdrawals left 53 subjects in the D‐ADM arm, 56 in the conventional care arm, and 23 in the GJ‐ADM arm (2:2:1 ratio). Subjects were followed through 24 weeks with major endpoints at Weeks 12, 16, and 24. Single application D‐ADM subjects showed significantly greater wound closure rates than conventional care at all three endpoints while all applications D‐ADM displayed a significantly higher healing rate than conventional care at Week 16 and Week 24. GJ‐ADM did not show a significantly greater healing rate over conventional care at any of these time points. A blinded, third party adjudicator analyzed healing at Week 12 and expressed “strong” agreement (κ = 0.837). Closed ulcers in the single application D‐ADM arm remained healed at a significantly greater rate than the conventional care arm at 4 weeks posttermination (100% vs. 86.7%; p = 0.0435). There was no significant difference between GJ‐ADM and conventional care for healed wounds remaining closed. Single application D‐ADM demonstrated significantly greater average percent wound area reduction than conventional care for Weeks 2–24 while single application GJ‐ADM showed significantly greater wound area reduction over conventional care for Weeks 4–6, 9, and 11–12. D‐ADM demonstrated significantly greater wound healing, larger wound area reduction, and a better capability of keeping healed wounds closed than conventional care in the treatment of chronic DFUs.
Overview
CoChat Summary
TL;DR
In a multicenter randomized controlled trial of 168 chronic diabetic foot ulcer subjects, a human acellular dermal matrix (D-ADM) achieved significantly higher healing rates than conventional care, while the active comparator human ADM (GJ-ADM) did not show significantly greater healing than conventional care at the studied endpoints. D-ADM also produced greater wound area reduction and better maintenance of healed wounds at 4 weeks posttermination.
Key findings
- In the per-protocol population, single-application D-ADM had significantly greater healing than conventional care at Week 12 (65.0% vs. 41.1%; HR 1.969; 95% CI 1.1–3.5; p=0.0123), Week 16 (82.5% vs. 48.1%; HR 2.397; 95% CI 1.4–4.1; p=0.0003), and Week 24 (89.7% vs. 67.3%; HR 2.107; 95% CI 1.3–3.5; p=0.0008). Median time to healing was 9.0 weeks for single-application D-ADM vs. 16.5 weeks for conventional care (p=0.0020).
- All-application D-ADM also showed significantly greater healing than conventional care at Week 16 (67.9% vs. 48.1%; HR 1.716; 95% CI 1.04–2.831; p=0.0283) and Week 24 (83.7% vs. 67.3%; HR 1.546; 95% CI 0.9821–2.435; p=0.0489). GJ-ADM did not show a significantly greater healing rate over conventional care at any time point, and no significant differences were seen between GJ-ADM and conventional care or between D-ADM and GJ-ADM.
- Healed ulcers in the single-application D-ADM arm remained closed at a significantly higher rate than conventional care at 4 weeks posttermination (100% [29/29] vs. 86.7% [26/30]; p=0.0435); GJ-ADM was 88.9% (8/9; p=0.8629 vs. conventional care). Single-application D-ADM demonstrated significantly greater average percent wound area reduction than conventional care for Weeks 2–24, while single-application GJ-ADM showed significantly greater reduction for Weeks 4–6, 9, and 11–12.
- No adverse events or serious adverse events were deemed related to the procedure or study product by site investigators. One death occurred in the D-ADM arm after healing and was determined not related to study procedures or product. Osteomyelitis was the most common severe infection: 5.6% in D-ADM, 5.9% in conventional care, and 10.7% in GJ-ADM.
Methods
- Prospective, multicenter, randomized, controlled, open-label trial enrolling 168 diabetic foot ulcer subjects at 13 outpatient wound care centers across 9 states; subjects were randomized 2:2:1 to D-ADM, conventional care, or GJ-ADM. ADM arms received one application and could receive one additional application if medically necessary; follow-up was through 24 weeks with major endpoints at Weeks 12, 16, and 24.
- Primary endpoint was proportion of chronic DFUs completely closed at 12 weeks, with complete closure defined as 100% reepithelialization without drainage or dressing requirements confirmed at two consecutive study visits 2 weeks apart. Secondary endpoints included proportion completely healed, time to closure, proportion of healed wounds remaining closed posttermination, percent wound area reduction, and safety.
- Analyses included Fisher’s exact test, ANOVA, Kaplan-Meier survivorship with Logrank (Mantel-Cox) tests, hazard ratios with 95% CIs, logistic regression, t tests, and Cohen’s kappa for interrater reliability; two-sided alpha was 0.05. A blinded third-party adjudicator assessed healing at Week 12 and expressed “strong” agreement (κ=0.837).
Limitations
- Stated: the trial was open-label and treatment could not be blinded to the implanting surgeon or subject because the ADM is visible on the wound surface; this was mitigated by blinded clinician review of wound images, laser-based wound area measurement, and a blinded third-party adjudicator. The GJ-ADM arm was not powered to detect a difference and was added only to establish a baseline ADM healing rate.
- Stated: the study was erroneously powered using healing rates from other human ADM studies that reported only single application with 12-week follow-up; all-subject healing did not become statistically significant until Week 15 even though percent wound area reduction was significant from Week 6. Multiple probability tests were applied without correcting related probabilities, and the effect of a second application was not considered during protocol development; timing criteria for second applications are not standardized. Wound depth data were not used because the Silhouette System had difficulty reliably determining depth.
- Stated/evident: the strict AHRQ healing definition may have artificially lowered the healing rate for as many as 9 D-ADM wounds (17% of the D-ADM arm) that could have been labeled healed in previous studies. The study was funded by LifeNet Health, the manufacturer of DermACELL, and some authors are employees of LifeNet Health (evident from the acknowledgements and conflict-of-interest statement).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 29 Not checked · 80 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the intent to treat population (Figure 4), single application D-ADM demonstrated significantly greater healing over conventional care through endpoints at Week 16 (66.0%vs. 37.7%; HR 5 1.918; 95% CI 5 1.139-3.23;p 5 0.0093)”
§ A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator > RESULTS
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“GJ-ADM did not show a significantly greater healing rate over conventional care at any time point.”
§ A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator > RESULTS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“while single application GJ-ADM showed significantly greater percent wound area reduction over conventional care for Weeks 4-6, 9, and 11-12”
§ A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator > RESULTS
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In a week by week analysis (Figure 5), statistical significance was seen for one application D-ADM versus conventional care at weeks 7-24.”
§ A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator > RESULTS
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Week 24 (70.0% vs. 49.3%;HR 5 1.589; 95% CI 5 0.9824-2.572;p 5 0.0442)”
§ A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator > RESULTS
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
29 more claims
Create a free account to see all 110 claims and every source verdict.
- Probably not a substantial claim. 47
- It may state two separate claims as one. 42
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the final follow-up wound area was similar between two treatment groups, the percentage area reduction (PAR) was demonstrated to be significantly increased in several studies [23, 26, 27, 31, 34].”
From Effectiveness and safety of dermal matrix used for diabetic foot ulcer: a systematic review and meta-analysis of randomized controlled trials (2024) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator > DISCUSSION
“The Kirsner et al. 43 study”
§ A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator > References
“43. Zelen CM, Orgill DP, Serena T, Galiano R, Carter MJ, DiDomenico LA, et al.”
Citations
Cites
Interrater reliability: The kappa statistic
McHugh, M. L. (2012) · Biochemia Medica · doi:10.11613/bm.2012.031 · Cited by 19,877
What's wrong with Bonferroni adjustments
Perneger, T. V. (1998) · BMJ · doi:10.1136/bmj.316.7139.1236 · Cited by 5,900
Global estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642
An overview of tissue and whole organ decellularization processes
Crapo, P. M., Gilbert, T. W., & Badylak, S. F. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.01.057 · Cited by 3,591
Preventing Foot Ulcers in Patients With Diabetes
Singh, N. K. (2005) · JAMA · doi:10.1001/jama.293.2.217 · Cited by 3,152
Human skin wounds: A major and snowballing threat to public health and the economy
Sen, C. K., Gordillo, G. M., Roy, S., Kirsner, R., Lambert, L., Hunt, T. K., Gottrup, F., Gurtner, G. C., & Longaker, M. T. (2009) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2009.00543.x · Cited by 2,965
The global burden of diabetic foot disease
Boulton, A. J. M., Vileikytė, L., Tennvall, G. R., & Apelqvist, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67698-2 · Cited by 2,578
A farewell to Bonferroni: the problems of low statistical power and publication bias
Nakagawa, S. (2004) · Behavioral Ecology · doi:10.1093/beheco/arh107 · Cited by 2,097
Intention-to-treat concept: A review
Gupta, S. (2011) · Perspectives in Clinical Research · doi:10.4103/2229-3485.83221 · Cited by 1,921
Why We (Usually) Don't Have to Worry About Multiple Comparisons
Gelman, A., Hill, J., & Yajima, M. (2012) · Journal of Research on Educational Effectiveness · doi:10.1080/19345747.2011.618213 · Cited by 1,274
Research works printed but not linked: 3
- CDC, 2014, National diabetes statistics report: estimates of diabetes and its burden in the United States
- Bakker K, 2005, Diabetes and foot care: time to act, Diabetic Foot J, 8, 120
- QinX CotterAT ChenS ChenJ WolfinbargerL.Gamma‐irradiated human acellular dermis: a potential treatment for wound and soft tissue defects. Proceedings of the Society for America Wound Care 21st Annual Meeting April 24–27 San Diego CA;2008.
Cited by
Diabetic Wound-Healing Science
Burgess, J. L., Wyant, W. A., Abujamra, B. A., Kirsner, R. S., & Jozic, I. (2021) · Medicina · doi:10.3390/medicina57101072 · Cited by 1,064
Update on management of diabetic foot ulcers
Everett, E., & Mathioudakis, N. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13569 · Cited by 913
Chronic Diabetic Wounds and Their Treatment with Skin Substitutes
Holl, J., Kowaléwski, C., Zimek, Z., Fiedor, P. S., Kamiński, A., Ołdak, T., Moniuszko, M., & Eljaszewicz, A. (2021) · Cells · doi:10.3390/cells10030655 · Cited by 382
Chen, P., Vilorio, N. C., Dhatariya, K., Jeffcoate, W., Lobmann, R., McIntosh, C., Piaggesi, A., Steinberg, J., Vas, P., Viswanathan, V., et al. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3644 · Cited by 246
Diabetic Foot Ulcers: Current Advances in Antimicrobial Therapies and Emerging Treatments
Ramirez-Acuña, J. M., Cardenas-Cadena, S. A., Marquez-Salas, P. A., Veloz, I. G., Perez-Favila, A., Cid-Báez, M. A., Flores‐Morales, V., & Martínez‐Fierro, M. L. (2019) · Antibiotics · doi:10.3390/antibiotics8040193 · Cited by 226
Current status and progress in research on dressing management for diabetic foot ulcer
Jiang, P., Li, Q., Luo, Y., Luo, F., Che, Q., Lu, Z., Yang, S., Yang, Y. L., Chen, X., & Cai, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1221705 · Cited by 211
Recent advances in decellularized biomaterials for wound healing
Xiao, H., Chen, X., Liu, X., Wen, G., & Yu, Y. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100589 · Cited by 130
Skin substitutes as treatment for chronic wounds: current and future directions
Vecin, N. M., & Kirsner, R. S. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1154567 · Cited by 105
Consensus on the application of negative pressure wound therapy of diabetic foot wounds
Ji, S., Liu, X., Huang, J., Bao, J., Chen, Z., Han, C., Hao, D., Hong, J., Hu, D., Jiang, Y., et al. (2021) · Burns & Trauma · doi:10.1093/burnst/tkab018 · Cited by 103
Vas, P. R. J., Rayman, G. A., Dhatariya, K., Driver, V. R., Hartemann, A., Löndahl, M., Piaggesi, A., Apelqvist, J., Attinger, C., & Game, F. L. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3284 · Cited by 90
Piaggesi, A., Läuchli, S., Bassetto, F., Biedermann, T., Marques, A. P., Najafi, B., Palla, I., Scarpa, C., Seimetz, D., Triulzi, I., et al. (2018) · Journal of Wound Care · doi:10.12968/jowc.2018.27.sup6a.s1 · Cited by 76
Scaffold-based delivery of mesenchymal stromal cells to diabetic wounds
Du, S., Zeugolis, D. I., & O’Brien, T. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03115-4 · Cited by 61
Tognetti, L., Pianigiani, E., Ierardi, F., Lorenzini, G., Casella, D., Liso, F. G., Pascalis, A. D., Cinotti, É., & Rubegni, P. (2021) · Dermatologic Therapy · doi:10.1111/dth.14987 · Cited by 58
Defining complete wound closure: Closing the gap in clinical trials and practice
Gould, L. J., & Li, W. W. (2019) · Wound Repair and Regeneration · doi:10.1111/wrr.12707 · Cited by 56
Updates on Recent Clinical Assessment of Commercial Chronic Wound Care Products
Sharma, A., Sharma, D., & Zhao, F. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300556 · Cited by 51
Chen, P., Campillo-Vilorio, N., Dhatariya, K., Jeffcoate, W. J., Lobmann, R., McIntosh, C. D., Piaggesi, A., Steinberg, J. S., VAS, P. R., Viswanathan, V., et al. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3786 · Cited by 47
Decellularized Extracellular Matrices for Skin Wound Treatment
Liang, R., Pan, R. L., He, L., Dai, Y., Jiang, Y., He, S., Li, B., & Li, Y. (2025) · Materials · doi:10.3390/ma18122752 · Cited by 46
Ventura, R. D., Padalhin, A., Kim, B., Park, M., & Lee, B. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.110663 · Cited by 43
Cazzell, S. M., Moyer, P. M., Samsell, B. J., Dorsch, K., McLean, J. B., & Moore, M. A. (2019) · Advances in Skin & Wound Care · doi:10.1097/01.asw.0000569132.38449.c0 · Cited by 42
Self-citationter Horst, B., Moiemen, N. S., & Grover, L. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-102546-8.00006-6 · Cited by 37
Tonaco, L. A. B., Gomes, F. S. L., Velásquez-Meléndez, G., Lopes, M. T. P., & Salas, C. E. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0684-2 · Cited by 32
Gordon, A. J., Alfonso, A. R., Nicholson, J., & Chiu, E. S. (2019) · Annals of Plastic Surgery · doi:10.1097/sap.0000000000002096 · Cited by 32
Montanaro, M., Meloni, M., Anemona, L., Giurato, L., Scimeca, M., Izzo, V., Servadei, F., Smirnov, A., Candi, E., Mauriello, A., et al. (2020) · The International Journal of Lower Extremity Wounds · doi:10.1177/1534734620945559 · Cited by 31
Öhnstedt, E., Tomenius, H. L., Frank, P., Roos, S., Vågesjö, E., & Phillipson, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020229 · Cited by 29
Monami, M., Scatena, A., Ragghianti, B., Miranda, C., Monge, L., Silverii, G. A., Uccioli, L., Vermigli, C., Syndrome, F. T. P. O. T. I. G. F. T. T. O. D. F., Bernetti, A., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02426-7 · Cited by 26
Application of a paste-type acellular dermal matrix for coverage of chronic ulcerative wounds
Jeon, M., & Kim, S. Y. (2018) · Archives of Plastic Surgery · doi:10.5999/aps.2018.00605 · Cited by 24
Samsell, B. J., McLean, J. B., Cazzell, S. M., Dorsch, K., Moyer, P. M., & Moore, M. A. (2019) · Journal of Wound Care · doi:10.12968/jowc.2019.28.sup9.s14 · Cited by 23
Self-citationAwasthi, A., Vishwas, S., Gulati, M., Corrie, L., Kaur, J., Khursheed, R., Alam, A., Alkhayl, F. F. A., Khan, F. R., Nagarethinam, S., et al. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103534 · Cited by 19
Bioengineered Skin for Diabetic Foot Ulcers: A Scoping Review
Primous, N. R., Elvin, P. T., Carter, K. V., Andrade, H. L., Fontaine, J. L., Shibuya, N., & Biguetti, C. C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051221 · Cited by 17
Banerjee, J., Lasiter, A., & Nherera, L. M. (2024) · Advances in Wound Care · doi:10.1089/wound.2023.0075 · Cited by 17
Huang, W., Chen, Y., Wang, N., Yin, G., Wei, C., & Xu, W. (2020) · Journal of Diabetes Research · doi:10.1155/2020/6245758 · Cited by 15
Sui, L., Xie, Q., Jiang, H.-T., & Li, X.-D. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01550-3 · Cited by 14
Hashemi, S.-S., Jowkar, S., Mahmoodi, M., Rafati, A., Mehrabani, D., Zarei, M., & Keshavarzi, A. (2018) · PubMed Central · Cited by 13
Update of Topical Interventions for Healing Diabetic Ulcers—A Systematic Review
de Sousa, G. P., Fontenele, M. K. A., da Rocha, R. B., & Cardoso, V. S. (2021) · The International Journal of Lower Extremity Wounds · doi:10.1177/15347346211013189 · Cited by 13
Mesenchymal stem cells-based drug delivery systems for diabetic foot ulcer: A review
Zhang, H., Yang, M., Xi, J.-Z., Yang, G., & Wu, Q. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i11.1585 · Cited by 13
(2021) · PubMed · Cited by 13
Kim, Y. H., Shim, H., Lee, J., & Kim, S. W. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082203 · Cited by 12
Mo, J., Huang, Y., Wang, Q., Zhong, H., Zhai, Z., Nong, Y., Yan, X., Huang, X., Huang, J., Yang, S., et al. (2022) · International Wound Journal · doi:10.1111/iwj.14005 · Cited by 11
Sarkar, S., & Poundarik, A. A. (2021) · Materialia · doi:10.1016/j.mtla.2021.101269 · Cited by 11
Chen, L., Yang, J., Wang, D., Jiang, J., Zhang, B., Zhao, Z., Chen, X., & Lv, D. (2023) · International Wound Journal · doi:10.1111/iwj.14341 · Cited by 10
Pacaccio, D. J., Cazzell, S. M., Halperin, G. J., Kasper, M. A., Neutel, J. M., O'Carroll, B. D., & Reyzelman, A. M. (2018) · Journal of Wound Care · doi:10.12968/jowc.2018.27.sup7.s28 · Cited by 9
Self-citationAhn, S. K., Choi, H. J., Lee, J. B., & Kim, J. H. (2019) · Journal of Wound Management and Research · doi:10.22467/jwmr.2018.00535 · Cited by 9
Current concepts for tissue transplant services for developing countries
Verdugo-Avello, F., Wychowaniec, J. K., Jimenez, M., Jiménez, S., & Gutiérrez, S. (2021) · Cell and Tissue Banking · doi:10.1007/s10561-020-09891-8 · Cited by 9
Immunomodulatory role of decellularized extracellular matrix in skin wound healing
Savitri, C., Park, H. S., Kim, Y., Jang, Y.-J., Hyun, J., Lee, D., Kang, M., Park, K. M., Bhang, S. H., & Park, K. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102672 · Cited by 8
Role of Innate Immune Cells in Chronic Diabetic Wounds
Raghavan, J. V., & Jhunjhunwala, S. (2023) · Journal of the Indian Institute of Science · doi:10.1007/s41745-022-00355-4 · Cited by 8
Davis, K. E., Killeen, A. L., Farrar, D., Raspovic, K. M., Berriman-Rozen, Z. D., Malone, M., & Lavery, L. A. (2020) · International Wound Journal · doi:10.1111/iwj.13479 · Cited by 8
The Challenge of Healing Wounds in Radiation-Injured Skin
Lavin, C. V., Kendig, C. B., Kawamoto-Duran, D., Tarter, J. G., Yao, H., Shibale, P., Sunwoo, P. S., Perrault, D. P., Longaker, M. T., & Wan, D. C. (2025) · Advances in Wound Care · doi:10.1177/21621918251400347 · Cited by 6
Caporusso, J., Motley, T. A., Lantis, J. C., Heisler, S., Hicks, A., Wu, S., & Reyzelman, A. M. (2025) · Wound Repair and Regeneration · doi:10.1111/wrr.70110 · Cited by 6
Self-citationApplication of paste-type acellular dermal matrix in hard-to-heal wounds
Kim, S. W., Shim, H., Lee, J., & Kim, Y. H. (2021) · Journal of Wound Care · doi:10.12968/jowc.2021.30.5.414 · Cited by 6
Cellular- and Acellular-Based Therapies: Skin Substitutes and Matrices
Cahn, B. A., & Lev‐Tov, H. A. (2020) · Updates in clinical dermatology · doi:10.1007/978-3-030-28872-3_15 · Cited by 6
Decellularized dermis allograft for the treatment of venous leg ulceration: the DAVE RCT
Onida, S., Tan, M. K. H., Balan, V., Heatley, F., Peerbux, S., Saghdaoui, L. B., Lane, T. R. A., Epstein, D. M., Gohel, M., Norrie, J. D., et al. (2025) · British journal of surgery · doi:10.1093/bjs/znae330 · Cited by 5
Lu, W., Hu, M. Q., Zheng, Z., Slaughter, J., Hingorani, A., & Oropallo, A. (2025) · JVS-Vascular Insights · doi:10.1016/j.jvsvi.2025.100215 · Cited by 5
Costa, I. G., Glazebrook, M. A., Lu, S. H., McLaren, A., & Gratzer, P. F. (2022) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2022.03.010 · Cited by 5
Mohammadi, A., Heydari, M. A., & Jamalpoor, Z. (2025) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-025-00458-1 · Cited by 5
Tissue Engineering Scaffolds: The Importance of Collagen
Correa-Araujo, L., Lara-Bertrand, A. L., & Silva-Cote, I. (2024) · Biochemistry · doi:10.5772/intechopen.1004077 · Cited by 5
Advances in preparation of acellular human dermis for tissue banking and transplantation
Stern, I., Barrera, V., Randles, M. J., & Rooney, P. (2024) · Cell and Tissue Banking · doi:10.1007/s10561-024-10153-0 · Cited by 4
A Narrative Review on Efficacy of Cell‐ and Tissue‐Based Therapies for Diabetic Foot Ulcer
Niroomand, B., Mohammadzadeh, I., Tabarzad, M., & Mohit, E. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202400335 · Cited by 4
Clinical and Postoperative Applications of Manuka Honey in Wound Healing: An Evidence‐Based Review
Alhabsi, A. N., Lawati, A. A., Hashmi, L. A., Al‐Isaii, F., Alghammari, A., Das, S., & Hashmi, S. A. (2026) · International Wound Journal · doi:10.1111/iwj.70939 · Cited by 3
Topical therapies for diabetic foot ulcers: a systematic review and network meta-analysis
Chen, L. J., Chen, J.-C., Lin, T., Shi, F., Chen, D., Wang, C., Gao, Y., Nair, H. K. R., & Ran, X. (2026) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2026-006026 · Cited by 3
Kim, M. J., Jeong, Y. S., Kim, T. W., Park, D. H., & Lee, I. J. (2022) · Frontiers in Materials · doi:10.3389/fmats.2022.1013245 · Cited by 3
Abdo, R., & Couch, A. L. (2024) · Journal of Wound Care · doi:10.12968/jowc.2024.0176 · Cited by 3
Amoroso, L., Agueci, S., Pianigiani, E., Ierardi, F., Calabrese, L., Rubegni, P., & Tognetti, L. (2024) · Life · doi:10.3390/life14101285 · Cited by 2
Acellular Dermal Matrix for Treatment of Diabetic Foot Ulcer: An Overview of Systematic Reviews
Lingyan, L., Han, Z., Li, J., Bingyang, H., Ma, Y., Peiwei, Q., Peifen, M., & Liwei, X. (2023) · The International Journal of Lower Extremity Wounds · doi:10.1177/15347346231201696 · Cited by 2
Onida, S., Heatley, F., Peerbux, S., Saghdaoui, L. B., Lane, T. R. A., Epstein, D. M., Gohel, M., Poskitt, K. R., Cullum, N. A., Norrie, J. D., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-041748 · Cited by 2
Scientific and Clinical Abstracts From WOCNext® 2023
(2023) · Journal of Wound Ostomy and Continence Nursing · doi:10.1097/won.0000000000000980 · Cited by 1
Jin, H., Shin, B., Kim, D., Seo, Y., Lee, Y., & Lee, S.-M. (2026) · Journal of Applied Biomaterials & Functional Materials · doi:10.1177/22808000261460977 · Cited by 1
Comparative Certainty of Evidence for Diabetic Foot Ulcer Therapies: A Narrative Synthesis
Mueller, S. M., Shi, H. D., Kaveti, A., Du, A., Clegg, D. J., Wagner, R., & Orgill, D. P. (2026) · Diabetology · doi:10.3390/diabetology7070131 · Cited by 1
Catella, J., Vouillarmet, J., Sigaudo‐Roussel, D., & Fromy, B. (2026) · Journal of Wound Care · doi:10.12968/jowc.2026.0331 · Cited by 1
Páramo-Pérez, M., González, H. A. P., Villarreal-Ríos, E., Lara, D. F., González, M. H., & López, A. S. (2021) · Revista de Cirugía · doi:10.35687/s2452-45492021006852 · Cited by 1
A gellan-based fluid gel carrier for spray delivery
ter Horst, B. (2019) · University of Birmingham Institutional Research Archive (University of Birmingham)
The use of Dermacell® Allograft in a diabetic patient with critical limb ischemia
Alexiou, V. G., Koutsias, S. G., & Bertasi, G. (2022) · Magna Scientia Advanced Biology and Pharmacy · doi:10.30574/msabp.2022.6.1.0068
Hanczaruk, B., Holl, J., Walewska, A., Karagüzel, D., Tynecka, M., Ciborowski, M., & Eljaszewicz, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-15978-7.00125-9
Sui, L., Xie, Q., Jiang, H.-T., & Li, X.-D. (2024) · Figshare · doi:10.6084/m9.figshare.25248776
Teng, J., Lin, F., Wang, L., Jiang, M., Li, Z., Yan, G., & Mi, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1800592
Adams, C., Gómez, I., Rodríguez, O., Vigil, A., Hernández, C., Ceballos, J., Cisterna, B. A., & Reginensi, D. (2026) · Materials · doi:10.3390/ma19091803
Chau, H. Y., Chen, M., Hsia, K., & Lin, C. (2026) · Current Problems in Surgery · doi:10.1016/j.cpsurg.2026.102135
Іваніцький, А. В., & Ivanitskyi, A. V. (2026) · DSpace BSMU
Ultra-fine Micronized Human Acellular Dermal Matrix Promotes Diabetic Wound Healing in a Mouse Model
Jin, H., Shin, B., Jang, K., Kim, D., Lee, S., Kim, J. Y., Lee, Y., & LEE, S.-M. (2026) · In Vivo · doi:10.21873/invivo.14491
Metadata
- Authors
- Cazzell, S., Vayser, D., Pham, H., Walters, J., Reyzelman, A., Samsell, B., Dorsch, K., & Moore, M.
- Affiliations
- Limb Preservation Platform Valley Vascular Surgical Associates Fresno California
- ILD Research Center San Diego California
- Boston University (US)
- Southern Arizona VA Health Care System (US)
- University of California, San Francisco (US)
- Lifenet Health (US)
- Corresponding author
- Cazzell, Shawn
- Venue
- Wound Repair and Regeneration
- Publisher
- Wiley
- Published
- 2017-05
- Volume
- 25
- Issue
- 3
- Pages
- 483-497
- ISSN
- 1067-1927 (ISSN-L)
- 1524-475X
- OpenAlex
- W2618058385
- Semantic Scholar
- ae43ab3357af91b591e3727c6adb7be1a7ed62c3
- Cited by
- 78
- References
- 46
- Citations by year
- 2026: 10 · 2025: 9 · 2024: 10 · 2023: 10 · 2022: 8 · 2021: 11 · 2020: 6 · 2019: 8 · 2018: 6
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Wound Repair and Regeneration (publishedVersion)
- PubMed (publishedVersion)
- Funders
- LifeNet Health
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetic Foot Ulcer Assessment and Management
- Health Sciences › Medicine › Surgery › Wound Healing and Treatments
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Keywords
- chronic diabetic foot ulcers, acellular dermal matrix, wound healing, wound closure, wound area reduction, conventional care
- MeSH terms
- Adult, Aged, Aged, 80 and over, Collagen, Female, Humans, Male, Middle Aged, Prospective Studies, United States, Wound Healing, Skin Transplantation, Treatment Outcome, Diabetic Foot, Negative-Pressure Wound Therapy, Standard of Care, Acellular Dermis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-13, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-13 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
